Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study

Allergy. 2021 Apr;76(4):1235-1238. doi: 10.1111/all.14200. Epub 2020 Feb 19.

Authors

Thomas Stranzl¹, Henrik Ipsen², Lars Harder Christensen¹, Thomas Eiwegger^{3

4

5}, Niels Johansen¹, Kaare Lund⁶, Peter Sejer Andersen¹

Affiliations

¹ ALK-Abelló A/S, Hørsholm, Denmark.
² HICON, Hillerød, Denmark.
³ Division of Immunology and Allergy, Department of Pediatrics, Food allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Canada.
⁴ Research Institute, The Hospital for Sick Children, Translational Medicine program, Toronto, Canada.
⁵ Department of Immunology, University of Toronto, Toronto, Canada.
⁶ Papermill Medical, Copenhagen, Denmark.

No abstract available

Keywords: Der p 23; HDM SLIT-tablets; cinical effect; diagnosis.

Publication types

Clinical Trial, Phase III
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Allergens
Animals
Antigens, Dermatophagoides
Humans
Hypersensitivity*
Immunoglobulin E
Pyroglyphidae
Sublingual Immunotherapy*
Tablets
Treatment Outcome

Substances

Allergens
Antigens, Dermatophagoides
Tablets
Immunoglobulin E